Karen A. Dawes, Director at Assertio Therapeutics, Inc (ASRT), sold 12,500 shares at $3.18 ($40K) on 2019-06-13, disclosed to the SEC on 2019-06-14.
Scheduled sale ($40k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |